• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    2/14/23 10:47:37 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    SC 13G/A 1 tm235085d2_sc13ga.htm SC 13G/A

     

     

     

    CUSIP No: 640491106

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Neogen Corporation
    (Name of Issuer)

     

    Common Stock, $0.16 par value per share

    (Title of Class of Securities)

     

    640491106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 640491106

     

      (1) Names of Reporting Persons
    Capital Ventures International
     
      (2)  Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      (3) SEC Use Only
     
      (4) Citizenship or Place of Organization
    Cayman Islands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    3,822,499 (1)(2)
     
    (6) Shared Voting Power
    8,291,607 (1)
     
    (7) Sole Dispositive Power
    3,822,499 (1)(2)
     
    (8) Shared Dispositive Power
    8,291,607 (1)
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    8,291,607 (1)
     
      (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      (11) Percent of Class Represented by Amount in Row (9)
    3.8%
     
      (12) Type of Reporting Person (See Instructions)
    CO
               

    (1) G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers which, together with Capital Ventures International, Susquehanna Advisors Group, Inc. and Susquehanna Fundamental Investments, LLC, may be deemed a group.  For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.  Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

    (2) Susquehanna Advisors Group, Inc. is the investment manager to Capital Ventures International and as such may exercise voting and dispositive power over the shares directly owned by Capital Ventures International.

     

     

     

     

    CUSIP No: 640491106

     

      (1) Names of Reporting Persons
    Susquehanna Advisors Group, Inc.
     
      (2)  Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      (3) SEC Use Only
     
      (4) Citizenship or Place of Organization
    Pennsylvania
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0 (1)(2)
     
    (6) Shared Voting Power
    8,291,607 (1)
     
    (7) Sole Dispositive Power
    0 (1)(2)
     
    (8) Shared Dispositive Power
    8,291,607 (1)
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    8,291,607 (1)
     
      (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      (11) Percent of Class Represented by Amount in Row (9)
    3.8%
     
      (12) Type of Reporting Person (See Instructions)
    CO
               

    (1) G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers which, together with Capital Ventures International, Susquehanna Advisors Group, Inc. and Susquehanna Fundamental Investments, LLC, may be deemed a group.  For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.  Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

    (2) Susquehanna Advisors Group, Inc. is the investment manager to Capital Ventures International and as such may exercise voting and dispositive power over the shares directly owned by Capital Ventures International.

     

     

     

     

    CUSIP No: 640491106

     

      (1) Names of Reporting Persons
    G1 Execution Services, LLC
     
      (2)  Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      (3) SEC Use Only
     
      (4) Citizenship or Place of Organization
    Illinois
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    12,158 (1)
     
    (6) Shared Voting Power
    8,291,607 (1)
     
    (7) Sole Dispositive Power
    12,158 (1)
     
    (8) Shared Dispositive Power
    8,291,607 (1)
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    8,291,607 (1)
     
      (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      (11) Percent of Class Represented by Amount in Row (9)
    3.8%
     
      (12) Type of Reporting Person (See Instructions)
    BD, OO
               

    (1) G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers which, together with Capital Ventures International, Susquehanna Advisors Group, Inc. and Susquehanna Fundamental Investments, LLC, may be deemed a group.  For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.  Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

     

     

     

     

    CUSIP No: 640491106

     

      (1) Names of Reporting Persons
    Susquehanna Fundamental Investments, LLC
     
      (2)  Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      (3) SEC Use Only
     
      (4) Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    268,856 (1)
     
    (6) Shared Voting Power
    8,291,607 (1)
     
    (7) Sole Dispositive Power
    268,856 (1)
     
    (8) Shared Dispositive Power
    8,291,607 (1)
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    8,291,607 (1)
     
      (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      (11) Percent of Class Represented by Amount in Row (9)
    3.8%
     
      (12) Type of Reporting Person (See Instructions)
    OO
               

    (1) G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers which, together with Capital Ventures International, Susquehanna Advisors Group, Inc. and Susquehanna Fundamental Investments, LLC, may be deemed a group.  For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.  Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

     

     

     

     

    CUSIP No: 640491106

     

      (1) Names of Reporting Persons
    Susquehanna Securities, LLC
     
      (2)  Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      (3) SEC Use Only
     
      (4) Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    4,188,094 (1)
     
    (6) Shared Voting Power
    8,291,607 (1)
     
    (7) Sole Dispositive Power
    4,188,094 (1)
     
    (8) Shared Dispositive Power
    8,291,607 (1)
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    8,291,607 (1)
     
      (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      (11) Percent of Class Represented by Amount in Row (9)
    3.8%
     
      (12) Type of Reporting Person (See Instructions)
    BD, OO
               

    (1) G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers which, together with Capital Ventures International, Susquehanna Advisors Group, Inc. and Susquehanna Fundamental Investments, LLC, may be deemed a group.  For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.  Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

     

     

     

     

    CUSIP No: 640491106

     

    Item 1.
      (a)

    Name of Issuer

     

    Neogen Corporation (the “Company”)

      (b)

    Address of Issuer’s Principal Executive Offices

    620 Lesher Place, Lansing, Michigan 48912

     
    Item 2(a).  

    Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock, $0.16 par value per share, of the Company (the “Shares”).

     

    (i)            Capital Ventures International

    (ii)           Susquehanna Advisors Group, Inc.

    (iii)          G1 Execution Services, LLC

    (iv)          Susquehanna Fundamental Investments, LLC

    (v)           Susquehanna Securities, LLC

     

    Item 2(b).  

    Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of Capital Ventures International is:

     

    P.O. Box 897

    Windward 1, Regatta Office Park

    West Bay Road

    Grand Cayman, KY1-1103

    Cayman Islands

     

    The address of the principal business office of G1 Execution Services, LLC is:

     

    175 W. Jackson Blvd.

    Suite 1700

    Chicago, IL 60604

     

    The address of the principal business office of each of Susquehanna Advisors Group, Inc., Susquehanna Fundamental Investments, LLC and Susquehanna Securities, LLC is:

     

    401 E. City Avenue

    Suite 220

    Bala Cynwyd, PA 19004

     

    Item 2(c).   Citizenship
    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    Item 2(d).   Title of Class of Securities
    Common Stock, $0.16 par value per share
    Item 2(e)  

    CUSIP Number

    640491106

     

     

     

     

    CUSIP No: 640491106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with rule 13d–1(b)(1)(ii)(K).
          If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                                        

     

    Item 4. Ownership
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned by Susquehanna Securities, LLC includes options to buy 91,400 Shares.

     

    The Company’s Quarterly Report on Form 10-Q, filed on January 9, 2023 indicates that there were 216,154,283 Shares outstanding as of November 30, 2022.

     
    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   x

     

     

     

     

    CUSIP No: 640491106

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
    Not applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
    Not applicable.
     
    Item 9. Notice of Dissolution of Group
       
    Not applicable.

     

    Item 10. Certification
       
    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 640491106

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2023

     

    CAPITAL VENTURES INTERNATIONAL   SUSQUEHANNA ADVISORS GROUP, INC.
         
    By: Susquehanna Advisors Group, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed    
         
    By: /s/ Brian Sopinsky   By: /s/ Brian Sopinsky
    Name: Brian Sopinsky   Name: Brian Sopinsky
    Title: Assistant Secretary   Title: Assistant Secretary

     

    G1 EXECUTION SERVICES, LLC  

    SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC

             
    By: /s/ Brian Sopinsky   By: /s/ Brian Sopinsky
    Name: Brian Sopinsky   Name: Brian Sopinsky
    Title: Secretary   Title: Assistant Secretary

     

    SUSQUEHANNA SECURITIES, LLC  
         
    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 640491106 

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney executed by Capital Ventures International in favor of Susquehanna Advisors Group, Inc., dated as of December 4, 2012*

    II

     

    Joint Filing Agreement

         
    *Previously Filed

     

     

     

     

    CUSIP No: 640491106

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Neogen Corporation, $0.16 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated: February 10, 2023

     

    CAPITAL VENTURES INTERNATIONAL   SUSQUEHANNA ADVISORS GROUP, INC.
         
    By: Susquehanna Advisors Group, Inc. pursuant to a Limited Power of Attorney    
         
    By: /s/ Brian Sopinsky   By: /s/ Brian Sopinsky
    Name: Brian Sopinsky   Name: Brian Sopinsky
    Title: Assistant Secretary   Title: Assistant Secretary

     

    G1 EXECUTION SERVICES, LLC

     

    SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC

             
    By: /s/ Brian Sopinsky   By: /s/ Brian Sopinsky
    Name: Brian Sopinsky   Name: Brian Sopinsky
    Title: Secretary   Title: Assistant Secretary

     

    SUSQUEHANNA SECURITIES, LLC  
         
    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

    Get the next $NEOG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neogen Announces Sale of Cleaners & Disinfectants Business

      Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global cleaners and disinfectants business to Kersia Group ("Kersia"), a global leader in biosecurity, disinfection and hygiene solutions, for $130 million in cash at closing plus contingent consideration tied to the future performance of the business. The transaction is expected to be accretive to margins and close in the first quarter of the Company's 2026 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds will be used to fully repay the $100 million drawn on the Company's revolving credit facili

      4/21/25 9:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Neogen with a new price target

      Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

      12/19/24 8:18:19 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Wells Fargo initiated coverage on Neogen with a new price target

      Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

      6/16/23 7:34:39 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen upgraded by William Blair

      William Blair upgraded Neogen from Mkt Perform to Outperform

      11/22/22 8:02:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    SEC Filings

    See more
    • Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/22/25 4:45:23 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Neogen Corporation

      10-Q - NEOGEN CORP (0000711377) (Filer)

      4/9/25 4:04:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/9/25 7:06:54 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 4:28:12 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 11:16:20 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/13/24 5:09:41 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 4:32:35 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 2:45:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Boehm William T bought $26,175 worth of shares (5,000 units at $5.24), increasing direct ownership by 16% to 36,214 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 3:34:30 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $5.15 and covered exercise/tax liability with 1,603 shares, increasing direct ownership by 30% to 12,955 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/2/25 1:48:58 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO Adent John Edward exercised 2,112 shares at a strike of $5.16, increasing direct ownership by 0.78% to 271,276 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:39:59 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operating Officer Jones Douglas Edward exercised 845 shares at a strike of $5.16 and covered exercise/tax liability with 291 shares, increasing direct ownership by 0.78% to 71,713 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:34:22 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Financials

    Live finance-specific insights

    See more
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter Earnings Release Date

      LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

      3/20/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Preliminary¹ Second-Quarter 2025 Results

      Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg

      1/10/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care